Loading... Please wait...
Sort by:


dossier-jpg.jpgDossier 
reports present unbiased and concise analysis based on interviews with leading industry experts on important trends and challenging issues affecting the pharma industry today. 

  • Payer Attitudes to Orphan Drug Pricing
    Learn More Payer Attitudes to Orphan Drug Pricing
    Payer Attitudes to Orphan Drug Funding The explosion of orphan drugs across Europe and the US is pushing healthcare finances towards breaking point according to payers. Requests for orphan drug designation have reached...
  • Adherence – What Do Pharma Really Know
    Learn More Adherence – What Do Pharma Really Know
    Adherence – What Do Pharma Really Know The entire industry is talking about patient centricity but are the right steps being taken to address the most fundamental patient issue: non-adherence? Is ‘big...
  • Biosimilars Real World Evidence: Proving the point
    Learn More Biosimilars Real World Evidence: Proving the point
    Biosimilars Real World Evidence: Proving the point Biosimilar manufacturers face an uphill struggle to fully mobilise their product portfolio. Against a background of aggressive defence strategies by originator...
  • MSL stakeholder engagement: meeting expectations
    Learn More MSL stakeholder engagement: meeting expectations
    MSL Stakeholder Engagement–Meeting Expectations In this report, FirstWord identifies practical solutions to the stakeholder engagement challenges faced by medical science liaisons (MSLs) teams in 2017. Discover...
  • What do Patients want from Pharma?: The Real Patient-Centric Perspective
    Learn More What do Patients want from Pharma?: The Real Patient-Centric Perspective
    What do Patients want from Pharma? How can pharma leverage patient insights to deliver the support they want?  Is patient centricity coming of age? The patient voice is becoming increasingly influential and...
  • The Future of Biosimilars in Europe
    Learn More The Future of Biosimilars in Europe
    Education is top priority as biosimilar mAbs enter the market With the recent approval of Celltrion’s Truxima, all eyes are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next...
  • Biomarkers and Companion Diagnostics - Payer views
    Learn More Biomarkers and Companion Diagnostics - Payer views
    Winning Payer Support for Companion Diagnostics & Biomakers How can you positively influence payer attitudes to biomarkers and companion diagnostics (CDx)? Biomarkers and CDx are critical to realising the...
  • Evidence Matters – Why Pharma Needs to Get Serious about Data
    Learn More Evidence Matters – Why Pharma Needs to Get Serious about Data
    Real World Evidence: Creating a forward-focused strategy In today’s highly scrutinised drugs marketplace, pockets continue to be squeezed and the list of demands from every quarter lengthens. Against this...
  • Charting MSL Activity and Performance (2017)
    Learn More Charting MSL Activity and Performance (2017)
    A unique survey-based report providing key insights and actionable intelligence about MSL activity and performance. Charting MSL Activity and Performance (2017) distils key findings from one of the most comprehensive...
  • Real World Data: Meeting Payer Needs
    Learn More Real World Data: Meeting Payer Needs
    How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...
  • How Payers Want to Work With Pharma
    Learn More How Payers Want to Work With Pharma
    How to effectively engage US and EU payers You’re speaking to payers, but are they listening?  Do you really understand their needs and concerns?  Is your approach to payer negotiations getting your...
  • Medical Affairs in Orphan Drugs
    Learn More Medical Affairs in Orphan Drugs
    Orphan drugs: Is your medical affairs team leading the fray or lagging behind?  Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...
  • Pulling the Data Puzzle Together: Being Payer-Centric
    Learn More Pulling the Data Puzzle Together: Being Payer-Centric
    Mapping data with payer needs. How to solve the data puzzle.  Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer...
  • Charting the Orphan Drug Development Pipeline
    Learn More Charting the Orphan Drug Development Pipeline
    Which are the most exciting areas of orphan drug research and where are the best opportunities? Global sales of drugs for orphan indications were estimated to be $114 billion in 2016, with sales forecast to rise to $209...
  • Biosimilars in Emerging Markets (2017)
    Learn More Biosimilars in Emerging Markets (2017)
    Biosimilars: Make the most of high risk emerging market opportunities  Emerging biosimilars markets are currently a $5billion opportunity with even more growth potential ahead. Lower drug costs and improved patient...
  • Biosimilars: US Payer Perspectives (2017)
    Learn More Biosimilars: US Payer Perspectives (2017)
    Will biosimilar provide a ‘magic bullet’ to drug prices in the US? Payers speak out…  Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers...

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved